Food And Drug Administration-Drugmaker Novo Nordisk-Health Regulators-Insulin

Novo Nordisk hit by U.S. delay to new insulin drug

The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring near Washington

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, said on Friday that U.S. health regulators had extended their review of its new ultra-long-acting insulin Tresiba, or degludec, to consider further data. The unexpected delay is a disappointment since degludec is a pivotal new product with which Novo hopes to consolidate its position in the fast-growing diabetes market. Shares in the group fell 3.1 percent by 0740 GMT. ... read more..

source:http://yhoo.it/KNZYpR